Avammune Therapeutics
PrivateLast Round
Series A
May 7, 2025
Total Funding Raised
$24M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Avammune Therapeutics is a biopharmaceutical company developing a pipeline of small-molecule drugs designed to modulate the innate immune system for treating cancer and autoimmune disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Avammune Therapeutics Comparables
Compare Avammune Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| IFM Therapeutics | 82% | |
| TXINNO Bioscience INC | 81% | |
| ImmuneSensor Therapeutics | 79% |
Avammune Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | May 7, 2025 | ||||
| Series A | May 7, 2024 | ||||
| Angel | Jul 15, 2022 | ||||
| Seed | Jul 9, 2019 |
Avammune Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The Chennai Angels | Angel |
| Shastra VC | Series A |
| 1Crowd | Series A |
| Capital 2B | Series A |
| IvyCap Ventures | Series A |
| Kotak Alternate Asset Managers | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors grew 349% MoM.
- May 13, 2026
Grew 21% QoQ, from 14 to 17 employees.
Avammune Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Avammune Therapeutics's valuation, stock price, and market status.
Is Avammune Therapeutics a public or private company?
Avammune Therapeutics is a private company.
What is the current stock price of Avammune Therapeutics?
Avammune Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Avammune Therapeutics worth (valuation)?
Valuation information for Avammune Therapeutics is not publicly available.
Can I buy Avammune Therapeutics stock?
Avammune Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Avammune Therapeutics's last funding round?
Avammune Therapeutics's most recent funding round was Series A on May 7, 2025.
Who are the main investors in Avammune Therapeutics?
Key investors in Avammune Therapeutics include The Chennai Angels, Shastra VC, Capital 2B, Kotak Alternate Asset Managers.
Will Avammune Therapeutics IPO soon?
No public IPO plans have been announced for Avammune Therapeutics.
How can I track Avammune Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Avammune Therapeutics's secondary market activity and sign up for updates.